Log in to your Inderes Free account to see all free content on this page.
SynAct Pharma
12.31
SEK
-1.52 %
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 following
-1.52%
+38.31%
+48.31%
+75.98%
+39.41%
+81.56%
-91.22%
+28.29%
+164.64%
synactpharma.com/en
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and various joint injuries. The subsidiary SynAct Pharma Aps was initially founded in 2012 and the parent company was established in 2016. The head office is located in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SYNACT
Daily low / high price
12.31 / 12.56
SEK
Market cap
508.36M SEK
Turnover
118.94K SEK
Volume
9.5K
Latest videos
Financial calendar
Extraordinary general meeting
13.12.2024
Annual report
18.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sanos Group NBCD | 9.6 % | 9.6 % |
Avanza Pension | 6.8 % | 6.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Nomination committee appointed ahead of AGM 2025 in SynAct Pharma AB
BioStock: New and larger shareholders back SynAct's capital raise - CEO comments
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio